A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo‐immunized patients
Phuong Vo(University of Washington Medical Center), Richard Childs(National Heart Lung and Blood Institute), Reem Shalabi(National Institutes of Health), Kamille A. West(National Institutes of Health Clinical Center), Brian Wells(National Institutes of Health), Emily McDuffee(National Institutes of Health), Geri Hawks(National Institutes of Health), Willy A. Flegel(National Institutes of Health Clinical Center), Georg Aue(National Institutes of Health), Tatyana Worthy(National Institutes of Health), Robert Reger(National Institutes of Health), Sharon Adams(National Institutes of Health Clinical Center), Lisa Cook(National Institutes of Health), Xin Tian(National Institutes of Health), Enkhtsetseg Purev(University of Colorado Denver)
Cited by 30
Related Papers
Molecular Basis of Weak D Phenotypes
|Blood|1999|336
Molecular Basis of Weak D Phenotypes
|Blood|1999|331
RHD gene deletion occurred in the Rhesus box
|Blood|2000|319
RHD positive haplotypes in D negative Europeans
|BMC Genetics|2001|310
Weak D alleles express distinct phenotypes
|Blood|2000|255